Beltran Pedro
President and CEO
Beltran Pedro has filed 5 SEC Form 4 filings (5 transaction rows) across 1 company, with disclosures dating back to 2026. 5 of those filings fall inside the rolling window. Most recent filing: Nov 20, 2026.
On the most recent filing, Beltran Pedro is listed as President and CEO at BridgeBio Oncology Therapeutics, Inc. Inside the rolling window, Beltran Pedro reported no open-market purchases and 1 open-market sale totaling $3K in BBOT.
Companies traded
Other insiders at BBOT
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$3K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Beltran Pedro made?
Beltran Pedro has filed 5 SEC Form 4 filings (5 transaction rows) across 1 company since 2026.
Which companies does Beltran Pedro trade?
Beltran Pedro has filed SEC Form 4 disclosures for 1 company, including BBOT.
When was Beltran Pedro's most recent SEC Form 4 filing?
Beltran Pedro's most recent SEC Form 4 filing on Tracefour is dated Nov 20, 2026.
What is Beltran Pedro's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Beltran Pedro is listed as President and CEO.
What is Beltran Pedro's total buy and sell value in the current window?
Inside the rolling retention window, Beltran Pedro bought $0 and sold $3K based on SEC Form 4 filings.
What was Beltran Pedro's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 1,870 BBOT shares on 2026-11-18, worth $3K, per SEC Form 4 filings.